ASF Standards · Ambulatory Clinic · Standard 9

Standard 9 — Aesthetic & Injectable Medicine

4 criteria · 3 non-negotiable · 1 core · Version 3.0

Criteria in this standard

9.1 — A Licensed Physician Oversees Every Injection, Even If Not the Injector
9.2 — Injectable Products Are Sourced From Verified, Traceable Suppliers
9.3 — Vascular Occlusion Is Recognised and Treated Within Minutes, Not Hours
9.4 — Patients Are Screened for Genuine Medical Suitability Before Treatment

9.1

A Licensed Physician Oversees Every Injection, Even If Not the Injector

Non-Negotiable

A licensed physician holds genuine, documented oversight of every injectable procedure performed at this facility, whether or not the physician personally administers each injection — not an arrangement where trained staff inject with no real physician accountability.

In plain terms: A licensed doctor genuinely supervises every injectable treatment — has assessed the patient, is reachable, and is accountable — even if a nurse gives the injection.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

Botulinum toxin and dermal fillers are prescription medicines with serious complications: vascular occlusion causing tissue death or blindness, infection, migration, anaphylaxis. In many jurisdictions they may only be administered under the direction of a doctor who has assessed the patient. 'Under the direction of' does not mean a name on a certificate; it means the doctor has seen the patient (in person or by video), approved the treatment plan, is contactable during the procedure, and is accountable for the outcome. A clinic where the doctor's name is on the wall but the doctor has never seen the patient has no medical oversight.

What good looks like

A specific, named physician holds genuine, documented oversight.
Oversight is real-time and immediate when a non-physician injects.
The physician can describe specific, real involvement in recent cases.

Common failure modes

No specific physician is named; oversight is a vague, general claim.
Oversight exists only as after-the-fact paperwork review.
The physician cannot describe any specific recent involvement.

Worked example

In practice

An aesthetic clinic with two nurse injectors and a 'medical director' who visited monthly.

BeforeThe medical director signed prescriptions in batches for patients he had not seen. Nurses assessed, planned, and injected. During a vascular occlusion event, the doctor was unreachable for 40 minutes. There was no documented prescriber assessment for any patient.

ActionThe clinic adopted a supervision model: every new patient has a video or in-person consultation with the prescribing doctor before first treatment, recorded in the notes; the doctor approves each treatment plan in writing; the doctor is on call by phone during all injection sessions with a 10-minute response commitment; the doctor reviews all adverse events within 24 hours. A second doctor was contracted to cover absences.

AfterThe Monitor reviewed 20 patient records: each had a documented prescriber consultation and plan approval. Reviewed the on-call rota and phone log showing three test calls answered within 10 minutes. Verified.

If you are starting from zero — do this first

Pull ten patient records: did the prescribing doctor assess this patient before treatment? Is it documented?
Ask: if a vascular occlusion happened right now, how fast could you reach the doctor?
Write a supervision agreement: consultation before treatment, plan approval, on-call availability.
Arrange cover for the doctor's absence.

The most common mistake: Calling a doctor who signs batch prescriptions for unseen patients a 'medical director.'

Self-assessment questions

1. Is there a specific, named licensed physician with documented oversight of injectable procedures here? — A specific person and a real, checkable oversight relationship, not an assumed general affiliation.
Evidence: Physician oversight documentation

2. If a non-physician performs the injection, is the physician's oversight genuine and immediate, not remote or after the fact? — Real-time availability and accountability, not a signature reviewed days later.
Evidence: Oversight protocol document

3. Can the physician describe their actual involvement in a recent case, specifically? — A real, specific example, not a general description of the arrangement.
Evidence: N/A — tested directly

Common reasons for a PARTIAL answer

A physician is named but is rarely physically present during procedures. — Named oversight without genuine availability doesn't provide real protection during a complication.
Oversight is real for complex procedures but looser for routine ones. — Complications can occur even in routine cases; the oversight standard shouldn't depend on perceived complexity.
The physician reviews cases in batches at the end of the week.

Implementation plan

When	What
Week 1	Confirm and document the specific overseeing physician and their real availability.
Week 2	Establish a real-time oversight protocol for non-physician injectors.
Week 3	Brief all staff on the specific oversight arrangement and escalation process.
Ongoing	Review oversight genuineness periodically, including physician availability records.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Oversight documentation review	Reviews documentation naming the specific overseeing physician and the nature of their oversight.
ASK	Physician involvement interview	Asks the physician to describe their actual, specific involvement in a recent injectable case.
OBSERVE	Real-time availability check	Checks whether physician oversight is genuinely immediate during procedures, not remote.

Supervisor tips

Ask the physician for a specific, recent case example, not a general description. — Specificity reveals whether oversight is genuine or a formality.
Ask a non-physician injector how they'd reach the physician during a complication, right now. — A confident, specific answer reveals genuine real-time oversight.

Evidence base

[49] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — establishes physician-level clinical oversight, proper patient selection, and technique as core risk-reduction requirements for injectable treatment.

Train your team: AMB-09 · Aesthetic Medicine on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

9.2

Injectable Products Are Sourced From Verified, Traceable Suppliers

Non-Negotiable

Every injectable product used is sourced from a verified, traceable supplier, with batch and lot records retained — not purchased through unverified channels where authenticity cannot be confirmed.

In plain terms: Every filler, toxin, and injectable comes from a verified, licensed supplier with batch and lot numbers recorded — never from a website, a colleague, or an unverifiable source.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

Counterfeit botulinum toxin and filler are a global problem. Fake products have caused botulism, blindness, and disfigurement. They are sold online at half price, in packaging indistinguishable from the real thing. The only protection is traceability: a supplier authorised by the manufacturer or the national regulator, with invoices, and the batch and lot number of every vial recorded against every patient. If a product is recalled or a patient has an adverse reaction, the clinic must be able to say exactly which vial from which batch was used. A clinic that buys from the cheapest source cannot.

What good looks like

All products are sourced from verified, traceable suppliers.
Batch and lot records are complete and linked to patient records.
Staff describe genuine awareness of counterfeit product risk.

Common failure modes

Sourcing channels cannot be verified or are informal.
Batch and lot records are incomplete or not retained.
Staff show no awareness of counterfeit product risk.

Worked example

In practice

An aesthetic clinic sourcing toxin and filler through several channels including an online marketplace.

BeforeStock came from an authorised distributor when available, an online site when cheaper, and occasionally from another practitioner. No batch numbers were recorded in patient notes. A patient developed an unusual reaction; the clinic could not say which vial or source had been used.

ActionThe clinic wrote a procurement policy: only manufacturer-authorised distributors, verified against the manufacturer's published list; every invoice filed; batch and lot number recorded in the patient record at every treatment; a stock register linking each vial to its supplier and patients. The online source was discontinued and remaining stock from it destroyed.

AfterThe Monitor sampled ten vials in stock and traced each to an authorised distributor invoice. Reviewed 15 patient records with batch numbers recorded. Verified.

If you are starting from zero — do this first

List every source you buy injectables from.
Check each against the manufacturer's authorised distributor list.
Start recording batch and lot numbers in every patient record.
Destroy stock you cannot trace.

The most common mistake: Assuming a product is genuine because the packaging looks right — counterfeit packaging is near-perfect.

Self-assessment questions

1. Is every injectable product sourced from a verified, traceable supplier, not an unverified or informal channel? — A checkable, legitimate supply chain, not just a lower price.
Evidence: Supplier verification record

2. Are batch and lot numbers retained for every product used, linked to the patient record? — Traceability that would allow a recall or adverse event investigation to actually work.
Evidence: Batch and lot tracking record

3. Can staff describe how they'd recognise a counterfeit or suspicious product? — Genuine awareness, not an assumption that sourcing alone guarantees authenticity.
Evidence: N/A — tested directly

Common reasons for a PARTIAL answer

Primary products are verified but occasional supplementary products are not. — Every injectable product carries the same real authenticity risk, not only the primary ones.
Batch numbers are recorded but not consistently linked to the specific patient treated. — Traceability requires the link to the patient, not just the product record alone.
Verification happened once at the start of a supplier relationship but isn't ongoing.

Implementation plan

When	What
Week 1	Review current suppliers for all injectable products against verification standards.
Week 2	Establish batch and lot tracking linked to patient records.
Week 3	Train staff on recognising counterfeit or suspicious product indicators.
Ongoing	Periodically reconfirm supplier legitimacy.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Supplier verification review	Reviews documentation confirming products are sourced from verified suppliers.
DOCUMENT	Batch tracking review	Reviews batch and lot records for completeness and linkage to patient records.
ASK	Counterfeit awareness interview	Asks staff how they would recognise a suspicious or counterfeit product.

Supervisor tips

Ask to see the actual supplier verification and batch records, not a general assurance. — Documented, specific records are the only real evidence of genuine traceability.
Ask staff directly what would make them suspicious of a product's authenticity. — Genuine awareness reveals itself in specific, real answers, not a memorized policy line.

Evidence base

[50] Counterfeit injectable products, including unapproved botulinum toxin and dermal filler formulations, are a recognised and actively monitored risk in aesthetic medicine, with regulatory bodies issuing specific warnings to both practitioners and patients about verifying product source and authenticity before use.

Train your team: AMB-09 · Aesthetic Medicine on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

9.3

Vascular Occlusion Is Recognised and Treated Within Minutes, Not Hours

Non-Negotiable

Staff performing filler injections are specifically trained to recognise the signs of vascular occlusion immediately, with hyaluronidase or the appropriate emergency treatment genuinely available on-site — not requiring the patient to be sent elsewhere before treatment can begin.

In plain terms: Everyone injecting filler can recognise the signs of a blocked blood vessel within minutes, and the antidote (hyaluronidase) is in the room, in date, with a protocol to use it.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

When filler enters an artery, the tissue it supplies dies within hours — and if the artery leads to the eye, the patient is blind within minutes. The signs — blanching, pain out of proportion, mottling, visual change — are subtle at first and easy to dismiss. The treatment is high-dose hyaluronidase injected immediately, repeated until circulation returns. A clinic without hyaluronidase in the room, without a protocol on the wall, and without staff who have rehearsed it, will lose the window. This is the single most serious emergency in aesthetic practice and the one most often unprepared for.

What good looks like

Staff are specifically trained to recognise early signs of vascular occlusion.
Appropriate emergency treatment is genuinely on-site and in date.
A specific, known escalation process exists beyond initial treatment.

Common failure modes

Training covers general complications without specific occlusion recognition.
Emergency treatment isn't on-site or is expired.
Staff are uncertain what happens if initial treatment isn't sufficient.

Worked example

In practice

An aesthetic clinic performing 50 filler treatments a week.

BeforeHyaluronidase was kept in the fridge in a back room, one vial, expired. No written protocol existed. Injectors had read about vascular occlusion but never rehearsed a response. The clinic's plan was to 'send the patient to hospital.'

ActionA vascular occlusion kit was assembled for each treatment room: hyaluronidase (multiple vials, in date, expiry checked weekly), aspirin, warm compresses, the protocol card. The protocol was based on current consensus guidance: recognise, stop, flood the area with hyaluronidase, massage, reassess every 15 minutes, repeat, escalate to ophthalmology if visual symptoms. All injectors completed a course and a quarterly simulation drill.

AfterThe Monitor found the kit in each room, in date, with the protocol posted. Asked an injector to describe the first three steps; she did without hesitation. Reviewed two drill records. Verified.

If you are starting from zero — do this first

Where is your hyaluronidase right now? Is it in date? How many vials?
Print the consensus vascular occlusion protocol and put it in every treatment room.
Assemble a kit per room and check expiry weekly.
Run a simulation drill this month.

The most common mistake: Keeping one vial of hyaluronidase somewhere in the building — occlusion needs multiple vials, in the room, now.

Self-assessment questions

1. Are staff specifically trained to recognise the early signs of vascular occlusion during and immediately after injection? — Specific, trained recognition, not general awareness that complications exist.
Evidence: Vascular occlusion recognition training record

2. Is hyaluronidase, or the appropriate treatment for the products used, genuinely available on-site, not requiring off-site sourcing? — Immediately available, not something ordered after a complication is recognised.
Evidence: On-site emergency treatment stock record

3. Is there a defined, immediate escalation process if a suspected occlusion doesn't respond to initial treatment? — A specific next step, not uncertainty about what happens if first-line treatment isn't enough.
Evidence: Escalation protocol

Common reasons for a PARTIAL answer

Training happened once at hiring but hasn't been refreshed since. — Rapid recognition under real pressure benefits from periodic reinforcement, not a single training session.
Hyaluronidase is stocked but its expiry date wasn't recently checked. — Expired emergency treatment provides no real protection when actually needed.
Recognition training is strong for the injector but not for supporting staff who might notice symptoms first.

Implementation plan

When	What
Week 1	Review current vascular occlusion recognition training for specificity and recency.
Week 2	Confirm on-site emergency treatment stock and expiry dates.
Week 3	Establish and brief staff on a specific escalation protocol.
Ongoing	Refresh recognition training periodically, including for supporting staff.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Recognition training review	Reviews training records for specific vascular occlusion recognition, not general complication awareness.
OBSERVE	On-site treatment stock check	Physically confirms hyaluronidase or appropriate treatment is genuinely on-site and in date.
ASK	Escalation protocol interview	Asks staff what happens if a suspected occlusion doesn't respond to initial treatment.

Supervisor tips

Ask to see the actual hyaluronidase stock and check its expiry date directly. — Physical verification is the only real evidence of genuine on-site availability.
Ask a supporting staff member, not just the injector, how they'd recognise a complication. — This reveals whether recognition training genuinely reaches everyone present, not just the injector.

Evidence base

[51] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — identifies prompt recognition and treatment of vascular occlusion, including high-dose hyaluronidase availability, as critical to preventing permanent tissue damage.

Train your team: AMB-09 · Aesthetic Medicine on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

9.4

Patients Are Screened for Genuine Medical Suitability Before Treatment

Core

Every patient undergoes a genuine medical suitability screening before treatment — relevant medical history, medications, prior reactions — not a booking process that moves directly from consultation to injection with no real screening step.

In plain terms: Before any aesthetic treatment, the patient's medical history, medications, allergies, and previous reactions are genuinely assessed — not skipped because they only came for a 'small' procedure.

Facility category	Crisis	Transition	Small	Standard
Applicability	N/A	Full	Full	Full

Why this matters

The patient on blood thinners will bruise badly and may bleed. The patient with an autoimmune condition may react to filler. The patient with body dysmorphic disorder should not be treated at all. The patient who had a previous granuloma from a different filler needs a different plan. None of this is visible without asking. Aesthetic clinics often treat the consultation as a sales conversation and skip the medical screen — and then face a complication that a five-minute history would have predicted. A structured screening form, reviewed by the prescriber, is the minimum.

What good looks like

Every patient undergoes genuine, structured screening before treatment.
Screening specifically covers medications, prior reactions, and relevant conditions.
A real example exists of screening changing a treatment decision.

Common failure modes

Screening is informal or skipped, moving directly to treatment.
Screening content is generic and doesn't probe relevant risk factors.
No example exists of screening ever changing a treatment decision.

Worked example

In practice

An aesthetic clinic where patients moved from a phone booking to treatment on the same visit.

BeforeThe intake form asked for name, contact details, and treatment wanted. No medical history, medication list, or allergy question. A patient on warfarin had extensive bruising and a haematoma after filler; another with a history of cold sores developed a severe herpes outbreak after lip filler with no antiviral prophylaxis.

ActionA medical screening form was introduced: current medications, bleeding disorders, autoimmune conditions, allergies, previous aesthetic treatments and reactions, pregnancy, mental health history including body image concerns, and a body dysmorphia screening question. The prescriber reviews it before approving treatment. Patients on anticoagulants or with cold sore history follow specific protocols.

AfterThe Monitor reviewed 20 patient records: all had completed screening forms reviewed and signed by the prescriber. Two showed treatment deferred based on screening. Verified.

If you are starting from zero — do this first

Look at your intake form. Does it ask about medications, allergies, and previous reactions?
Add a one-page medical screen with a body image question.
Require prescriber review before any treatment.
Write protocols for anticoagulants and herpes history.

The most common mistake: Treating aesthetic patients as customers rather than patients — skipping the history because it might discourage the sale.

Self-assessment questions

1. Does every patient undergo a genuine medical suitability screening before treatment, not just a booking conversation? — A real, structured screening step, not an informal chat covering only what the patient happens to mention.
Evidence: Screening documentation

2. Does screening specifically cover relevant medications, prior reactions, and medical conditions that change risk? — Specific, relevant questions, not a generic intake form.
Evidence: Screening content review

3. Where screening identifies a relevant risk factor, does this genuinely change the treatment decision? — Screening that never changes an outcome isn't providing real protection.
Evidence: N/A — tested directly

Common reasons for a PARTIAL answer

Screening happens for new patients but isn't repeated for returning ones. — A patient's medical situation can change meaningfully between visits.
Screening covers medications but not prior reaction history specifically. — Prior reaction history is one of the strongest predictors of future risk.
Screening identifies a risk factor but the decision to proceed anyway isn't documented with reasoning.

Implementation plan

When	What
Week 1	Review current screening practice for genuine structure and content.
Week 2	Build or strengthen a screening tool covering medications, prior reactions, and relevant conditions.
Week 3	Establish screening for returning patients, not only new ones.
Ongoing	Document reasoning whenever a screening-identified risk factor doesn't change the treatment decision.

How the Monitor verifies this

Method	What	Detail
DOCUMENT	Screening documentation review	Reviews a sample of patient records for genuine, structured screening before treatment.
DOCUMENT	Screening content review	Reviews the screening tool for coverage of medications, prior reactions, and relevant conditions.
ASK	Risk-factor response interview	Asks staff for a real example where screening identified a risk factor that changed the treatment plan.

Supervisor tips

Ask for a real example where screening changed what was done for a patient. — A real example reveals whether screening is genuine practice or a formality.
Check whether screening is repeated for returning patients. — This is a common, specific gap — screening often concentrates only on new-patient intake.

Evidence base

[52] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — identifies careful pretreatment patient selection as an essential risk-reduction step, distinct from general consultation.

Train your team: AMB-09 · Aesthetic Medicine on GMJ Academy →

This course teaches practical implementation of this standard. Free to enroll. ASF certificate on completion.

← Ambulatory Clinic Standards — all standards
Self-assess against these criteria →
← Standard 8 — Dental Practice
Standard 10 — Longevity & IV Therapy →